Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that wo...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Foxwell, B, Andreakos, E, Brennan, F, Feldmann, M, Smith, C, Conron, M
Natura:	Journal article
Lingua:	English
Pubblicazione:	2003

Documenti analoghi

Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717.
di: Sumariwalla, P, et al.
Pubblicazione: (2009)

Cytokines and anti-cytokine biologicals in autoimmunity: present and future.
di: Andreakos, E, et al.
Pubblicazione: (2002)

Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
di: Foxwell, B, et al.
Pubblicazione: (2000)

Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist.
di: Neve, R, et al.
Pubblicazione: (1996)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
di: Brennan, F, et al.
Pubblicazione: (1995)

Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
di: Andreakos, E, et al.
Pubblicazione: (2004)

Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue.
di: Sacre, S, et al.
Pubblicazione: (2007)

IκB kinase 2 but not NF-κB-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction
di: Andreakos, E, et al.
Pubblicazione: (2003)

Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction.
di: Andreakos, E, et al.
Pubblicazione: (2003)

NF-κB-inducing kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin β receptor activation of NF-κB in primary human fibroblasts
di: Smith, C, et al.
Pubblicazione: (2001)

NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts.
di: Smith, C, et al.
Pubblicazione: (2001)

What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
di: Feldmann, M
Pubblicazione: (1996)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
di: Maini, R, et al.
Pubblicazione: (1995)

Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells.
di: Cope, A, et al.
Pubblicazione: (1993)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
di: Maini, R, et al.
Pubblicazione: (1999)

The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis.
di: Andreakos, E, et al.
Pubblicazione: (2005)

Endotoxin signaling in human macrophages: signaling via an alternate mechanism.
di: Sacre, S, et al.
Pubblicazione: (2004)

Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
di: Scallon, B, et al.
Pubblicazione: (1995)

High-efficiency gene transfer into nontransformed cells: utility for studying gene regulation and analysis of potential therapeutic targets.
di: Horwood, N, et al.
Pubblicazione: (2002)

TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion.
di: Ciesielski, C, et al.
Pubblicazione: (2002)

Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination.
di: Wales, J, et al.
Pubblicazione: (2007)

Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination
di: Wales, J, et al.
Pubblicazione: (2007)

TNFα-induced macrophage chemokine secretion is more dependent on NF-κB expression than lipopolysaccharides-induced macrophage chemokine secretion
di: Ciesielski, C, et al.
Pubblicazione: (2002)

The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the tumour necrosis factor receptor polymorphism incriminated in multiple sclerosis
di: Watts, L, et al.
Pubblicazione: (2018)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
di: Feldmann, M, et al.
Pubblicazione: (2020)

Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA.
di: Turner, M, et al.
Pubblicazione: (1988)

Molecular therapeutic targets in rheumatoid arthritis.
di: Sacre, S, et al.
Pubblicazione: (2005)

The structure of tumour necrosis factor--implications for biological function.
di: Jones, E, et al.
Pubblicazione: (1990)

Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.
di: Williams, R, et al.
Pubblicazione: (2000)

Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis.
di: Feldmann, M, et al.
Pubblicazione: (1994)

Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.
di: Andreakos, E, et al.
Pubblicazione: (2006)

Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases.
di: Taylor, P, et al.
Pubblicazione: (2004)

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.
di: Brennan, F, et al.
Pubblicazione: (1997)

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
di: Furst, D, et al.
Pubblicazione: (2000)

Tumour necrosis factor.
di: Van Der Merwe, P
Pubblicazione: (1988)

Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis.
di: Brennan, F, et al.
Pubblicazione: (2002)

Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
di: Andreakos, E, et al.
Pubblicazione: (2003)

Tumor necrosis factor-alpha (TNF) triggers a cytokine cascade yielding postoperative cognitive decline
di: Terrando, N, et al.
Pubblicazione: (2010)

VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2.
di: Kiriakidis, S, et al.
Pubblicazione: (2003)

VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2.
di: Kiriakidis, S, et al.
Pubblicazione: (2003)